Wednesday, June 10, 2026

Patent intelligence · WO

WO 2009084970

3-N-PHÉNYL-1,3,4-OXADIAZOLONES 5-O-SUBSTITUÉES POUR UNE UTILISATION MÉDICALE

granted A61K 31/ 4245 A IA61P 9/ 00 A IA61P 11/ 00 A IA61P 25/ 00 A I
Status granted
Pipeline programs 6
Years to expiry 3
Applicant portfolio 3
Patent details — WO 2009084970
Jurisdiction
WO
Status
granted
Grant date
Jul 9, 2009
Expiration
Jul 4, 2029
CPC classes
A61K 31/ 4245 A I, A61P 9/ 00 A I, A61P 11/ 00 A I, A61P 25/ 00 A I
View on Google Patents ↗

Quick answer

WO 2009084970 (3-N-PHÉNYL-1,3,4-OXADIAZOLONES 5-O-SUBSTITUÉES POUR UNE UTILISATION MÉDICALE) is held by BIAL PORTELA & COMPANHIA S A [PT]. Status: granted. Granted Jul 9, 2009. Expires Jul 4, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 4245 A I, A61P 9/ 00 A I, A61P 11/ 00 A I, A61P 25/ 00 A I, A61P/100, A61P/104

More from BIAL PORTELA & COMPANHIA S A [PT]

Related pharmaceutical patents in our USPTO index.

  1. CA 2723411

    PROCEDE

    BIAL PORTELA & COMPANHIA S A [PT] · Expires Nov 7, 2029

    granted
  2. TW 200942531

    Crystal forms of a nitrocatechol

    BIAL PORTELA & COMPANHIA S A [PT] · Expires Oct 11, 2029

    granted

Frequently asked questions

What is US patent 2009084970?

WO 2009084970 (3-N-PHÉNYL-1,3,4-OXADIAZOLONES 5-O-SUBSTITUÉES POUR UNE UTILISATION MÉDICALE) is held by BIAL PORTELA & COMPANHIA S A [PT]. Status: granted. Granted Jul 9, 2009. Expires Jul 4, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2009084970?

BIAL PORTELA & COMPANHIA S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.

When does WO 2009084970 expire?

Our index shows an expiration date of Jul 4, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.